Company / Cash & Equivalents
Phathom Pharmaceuticals, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$130.0M
FY2025
5-year range
$130.0M / $381.4M
FY2021-FY2025
Trend
-56.3%
vs FY2024
Sector context
#122 of 207
Health Care
What the data says
At $130M, Phathom Pharmaceuticals, Inc.'s cash & equivalents ranks #122 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 8 years, ranging from $879,000 in FY2018 to $381M in FY2023.
Based on SEC 10-K filings.
$130M in FY2025 with a 5-year CAGR of -14.7%.
Declined from $381M to $130M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.8%
- 5-Year CAGR
- -14.7%
- 10-Year CAGR
- -
Sector benchmark
#122 of 207 in Health CareTop 59% of 207This company $130.0M Sector average $669.5M
▼
-80.6% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.7%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 56.3% year-over-year.
- Ranks #122 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $130.0M | -56.3% |
| FY2024 | $297.3M | -22.1% |
| FY2023 | $381.4M | +145.5% |
| FY2022 | $155.4M | -15.2% |
| FY2021 | $183.3M | -36.3% |
| FY2020 | $287.5M | +17.9% |
| FY2019 | $243.8M | +27632.1% |
| FY2018 | $879.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026